Relugolix Dosage

Medically reviewed by Drugs.com. Last updated on May 5, 2023.

Usual Adult Dose for Prostate Cancer

Loading Dose: 300 mg orally once on the first day
Maintenance Dose: 120 mg orally once a day

Comment:

• Treatment is usually continued upon development of nonmetastatic or metastatic castration-resistant prostate cancer in patients treated with GnRH receptor agonists and antagonists.

Use: For the treatment of adult patients with advanced prostate cancer

Renal Dose Adjustments

Data not available.

Liver Dose Adjustments

Data not available.

Dose Adjustments

USE WITH P-GP INHIBITORS:

• Coadministration should be avoided.
• If unavoidable, take this drug and separate dosing 6 hours apart.
• If a short course with P-gp inhibitor is required, treatment with this drug may be interrupted for up to two weeks.
• If treatment is interrupted for more than 7 days, resume with a 360 mg loading dose on the first day and continue with 120 mg once a day.

USE WITH A COMBINED P-GP AND STRONG CYP450 3A INDUCERS:

• Coadministration Should be avoided.
• If unavoidable, increase the dose of this drug to 240 mg once a day.
• May resume at the recommended dose after discontinuation of the combined P-gp and strong CYP450 3A inducer.

Precautions

CONTRAINDICATIONS:

• None

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available.

Other Comments

Administration advice:

• The tablets should be swallowed whole.
• Do not to crush or chew tablets.
• This drug can be taken with or without food at approximately the same time each day.
• Take a missed dose as soon as possible.
• If a dose is missed and cannot be taken within 12 hours, skip that dose and take the next dose at the usual time.
• If treatment is interrupted for greater than 7 days, restart with a loading dose of 360 mg on the first day and continue with a dose of 120 mg once a day.

Storage Requirements:

• Store at room temperature.
• Do not store above 30C (86F).

Monitoring:

• Cardiovascular: ECG
• Endocrine: Prostate specific antigen levels
• Metabolic: Serum electrolytes

Patient advice:

• Advise the patient to read the FDA-approved patient labeling.
• Inform patients that this drug can be harmful to a developing fetus and can cause loss of pregnancy.
• Advise males with female partners of reproductive potential to use effective contraception during therapy and for at least 2 weeks after the last dose.
• Advise patients that this drug may prolong the QT interval and to report any signs of symptoms of QT prolongation.
• Inform patients that this drug may cause hot flashes, flushing of the skin, increased weight, decreased sex drive, and difficulties with erectile function.
• Inform patients that this drug may cause infertility.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer